Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Rooney

Showing results (71-80 of 165) with videos related to

Pageof 17
Sort By:
Lancet (London, England)|December 7, 1991
Prevention of ultraviolet-light-induced herpes labialis by sunscreenJ F Rooney, Y Bryson, M L Mannix, et al.
Antimicrobial Agents and Chemotherapy|July 1, 1987
Clinical isolate of herpes simplex virus type 2 that induces a thymidine kinase with altered substrate specificityM N Ellis, P M Keller, J A Fyfe, et al.
Antimicrobial Agents and Chemotherapy|September 16, 1998
Safety, pharmacokinetics, and antiretroviral activity of intravenous 9-[2-(R)-(Phosphonomethoxy)propyl]adenine, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adultsS G Deeks, P Barditch-Crovo, P S Lietman, et al.
AIDS Research and Human Retroviruses|March 1, 1993
Cutaneous disorders and viral gene expression in HIV-1 transgenic miceJ B Kopp, J F Rooney, C Wohlenberg, et al.
Sexually Transmitted Diseases|April 1, 1989
Effect of oral acyclovir treatment on symptomatic and asymptomatic virus shedding in recurrent genital herpesS E Straus, M Seidlin, H E Takiff, et al.
Modern Problems of Pharmacopsychiatry|January 1, 1970
The neuroleptics. 7. Classification of mental disordersJ E Cooper, J R Ewalt, P H Guilmot, et al.
Chemical Science|November 28, 2025
Gas exclusion zones in Type II porous liquidsCathal F Kelly, Sergio F Fonrouge, José L Borioni, et al.
AIDS (London, England)|May 25, 2010
A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy: ACTG 5206Marisa Tungsiripat, Douglas Kitch, Marshall J Glesby, et al.
Plos One|April 19, 2012
Safety and adherence to intermittent pre-exposure prophylaxis (PrEP) for HIV-1 in African men who have sex with men and female sex workersGaudensia Mutua, Eduard Sanders, Peter Mugo, et al.
The Lancet. HIV|February 6, 2023
Pregnancy and neonatal safety outcomes of timing of initiation of daily oral tenofovir disoproxil fumarate and emtricitabine pre-exposure prophylaxis for HIV prevention (CAP016): an open-label, randomised, non-inferiority trialDhayendre Moodley, Carl Lombard, Vani Govender, et al.
Pageof 17

Showing results (71-80 of 165) with videos related to

Sort By:
Pageof 17
Lancet (London, England)|December 7, 1991
Prevention of ultraviolet-light-induced herpes labialis by sunscreenJ F Rooney, Y Bryson, M L Mannix, et al.
Antimicrobial Agents and Chemotherapy|July 1, 1987
Clinical isolate of herpes simplex virus type 2 that induces a thymidine kinase with altered substrate specificityM N Ellis, P M Keller, J A Fyfe, et al.
Antimicrobial Agents and Chemotherapy|September 16, 1998
Safety, pharmacokinetics, and antiretroviral activity of intravenous 9-[2-(R)-(Phosphonomethoxy)propyl]adenine, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adultsS G Deeks, P Barditch-Crovo, P S Lietman, et al.
AIDS Research and Human Retroviruses|March 1, 1993
Cutaneous disorders and viral gene expression in HIV-1 transgenic miceJ B Kopp, J F Rooney, C Wohlenberg, et al.
Sexually Transmitted Diseases|April 1, 1989
Effect of oral acyclovir treatment on symptomatic and asymptomatic virus shedding in recurrent genital herpesS E Straus, M Seidlin, H E Takiff, et al.
Modern Problems of Pharmacopsychiatry|January 1, 1970
The neuroleptics. 7. Classification of mental disordersJ E Cooper, J R Ewalt, P H Guilmot, et al.
Chemical Science|November 28, 2025
Gas exclusion zones in Type II porous liquidsCathal F Kelly, Sergio F Fonrouge, José L Borioni, et al.
AIDS (London, England)|May 25, 2010
A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy: ACTG 5206Marisa Tungsiripat, Douglas Kitch, Marshall J Glesby, et al.
Plos One|April 19, 2012
Safety and adherence to intermittent pre-exposure prophylaxis (PrEP) for HIV-1 in African men who have sex with men and female sex workersGaudensia Mutua, Eduard Sanders, Peter Mugo, et al.
The Lancet. HIV|February 6, 2023
Pregnancy and neonatal safety outcomes of timing of initiation of daily oral tenofovir disoproxil fumarate and emtricitabine pre-exposure prophylaxis for HIV prevention (CAP016): an open-label, randomised, non-inferiority trialDhayendre Moodley, Carl Lombard, Vani Govender, et al.
Pageof 17